View Future GrowthNewcelX 過去の業績過去 基準チェック /06NewcelXの収益は年平均-9.7%で減少しているが、Biotechs業界はgrowingで36.2%年平均の収益となった。主要情報-9.72%収益成長率10.59%EPS成長率Biotechs 業界の成長17.04%収益成長率n/a株主資本利益率-114.48%ネット・マージンn/a前回の決算情報31 Dec 2025最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Jul 02NewcelX Ltd. Announces Successful FDA Pre-IND Meeting With Clear Path Forward For NCEL-101 Toward Starting Clinical Trials For Type 1 DiabetesNewcelX Ltd. announced the successful completion of its Type B Pre-IND meeting with the U.S. Food and Drug Administration. The agency provided constructive feedback and alignment on the Company's proposed development strategy, providing clarity regarding the regulatory pathway toward launching a clinical trial of NCEL-101 for type 1 diabetes in combination with Eledon Pharmaceuticals' anti-CD40L antibody, tegoprubart, an investigational immunomodulatory agent. The meeting results represent a significant milestone toward the clinical development of an innovative treatment paradigm targeting a potential functional cure for type 1 diabetes. The FDA provided favorable feedback on NewcelX's Chemistry, Manufacturing, and Controls processes and preclinical program allowing the Company to proceed toward its Investigational New Drug enabling activities. Combining NCEL-101, an enriched stem cell-derived islet product candidate, with Eledon's anti-CD40L monoclonal antibody, tegoprubart, serving as the cornerstone of a calcineurin inhibitor-free immunosuppressive regimen is designed to enable durable graft survival and function, with the goals of achieving outcomes comparable to donor human islet transplantation. This approach is supported by recently reported results from a 12-patient investigator-initiated study at University of Chicago Medicine in patients with type 1 diabetes, where tegoprubart-based immunosuppression preserved transplanted islet function and maintained durable immune protection. Tegoprubart has been used as an investigational immunosuppressive agent in more than 100 transplant recipients across studies conducted under multiple FDA-cleared IND applications. This body of clinical transplant experience provides important safety, dosing, and immunologic insights that are directly relevant to islet cell replacement therapies and support the planned advancement of NCEL-101. NCEL-101, leveraging a differentiated enrichment process, has demonstrated favorable results in preclinical studies and a supportive safety profile with the following qualities: ~60% Beta cells co express insulin and NKX6.1; MAFA expression, a transcription factor critical for Beta cells maturation and glucose dependent insulin secretion; 99.98% endocrine lineage, implying minimal, if any, off target non-endocrine population; More than 96% of cells are non-proliferative, as donor human islets.ライブニュース • Jul 01NewcelX Advances NCEL-101 After Positive FDA Pre-IND Meeting for Type 1 DiabetesNewcelX reported a successful FDA Pre-IND meeting for its lead cell therapy candidate NCEL-101, developed in combination with Eledon Pharmaceuticals’ tegoprubart for type 1 diabetes, with the agency providing constructive feedback and outlining a clear path toward IND-enabling activities. The FDA’s favorable view of NewcelX’s manufacturing and preclinical plans allows the company to progress toward formal IND submission, which is a key step before human clinical trials can begin and directly affects the potential timing of its type 1 diabetes program. NewcelX shares trade at US$3.66, with the stock up 75.1% year to date, indicating that the market has already reacted to recent developments around the company’s pipeline. This update moves NCEL-101 from concept toward a more defined regulatory track, while also concentrating risk around execution on IND-enabling work, manufacturing readiness, and future trial design.お知らせ • Jun 15NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential Of Its Stem Cell Technology PlatformNewcelX announced the publication of a peer-reviewed study in Stem Cell Reports, investigating the potential of AstroRx, a clinical-grade human embryonic stem cells (hESC)-derived astrocyte therapy, which recently completed a successful Phase 1/2a clinical trial in amyotrophic lateral sclerosis (ALS), as a novel and translationally relevant cell therapy for multiple sclerosis (MS), and other chronic demyelinating diseases. The publication further validates NewcelX’s ability to develop novel cell therapies through its stem cell technology platform, designed to generate scalable therapeutic assets across multiple applications. The study, titled “Pro-repair properties of a human embryonic stem cell–derived astrocyte cell therapy in experimental multiple sclerosis,” was developed in collaboration with researchers at several highly regarded institutions, including the Hebrew University of Jerusalem Hadassah Medical School. Data demonstrated that AstroRx addresses key barriers to remyelination by enhancing myelin debris clearance, sustaining a pro-repair inflammatory environment, and promoting the differentiation of oligodendrocyte progenitor cells (OPCs) into mature oligodendrocytes. These effects were observed both in-vitro and in an in-vivo lysolecithin-induced demyelination model. Key findings from the study include the potential for AstroRx® to: enhance myelin debris clearance by microglia, support lymphocyte-mediated immune regulation, and accelerate oligodendrocyte progenitor cell (OPC) differentiation into oligodendrocytes.お知らせ • Jun 09NewcelX Ltd., Annual General Meeting, Jun 30, 2026NewcelX Ltd., Annual General Meeting, Jun 30, 2026, at 14:00 W. Europe Standard Time. Location: baker mckenzie switzerland ag, holbeinstrasse 30, 8034 switzerland, zurich Switzerlandお知らせ • May 01NewcelX Ltd. announced that it has received $1.349994 million in fundingOn April 30, 2026, NewcelX Ltd. closed the transaction.お知らせ • Apr 02NewcelX Ltd. announced that it expects to receive $1.349994 million in fundingNewcelX Ltd. announced that it has entered into a securities purchase agreement to issue 490,907 common shares or pre-funded warrants at an issue price of $2.75 per share for gross proceeds of $1,349,994.25 and one series of warrants to purchase 687,270 common shares at an exercise price of $3.025 per share for aggregate proceeds of $1,349,994.25 on April 1, 2026. The offering includes participation from existing shareholders and is expected to close on or about April 15, 2026, subject to the satisfaction of customary closing conditions. The securities are being issued in a private placement under section 4(a)(2) of the securities act of 1933, as amended), and Regulation D promulgated thereunder and have not been registered under the securities act, or applicable state securities laws.New Risk • Mar 31New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$8.57m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-₪51m). Earnings have declined by 6.8% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$8.57m market cap). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (11% average weekly change).New Risk • Mar 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪2.2m free cash flow). Negative equity (-₪51m). Earnings have declined by 6.8% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (US$11.9m market cap).お知らせ • Jan 13Newcelx Ltd. Announces Positive Results from International Collaborative StudyNewcelX Ltd. reported the results of an international collaborative research study investigating advanced biomaterial strategies to support the delivery and function of stem cell-derived islets for the treatment of Type 1 Diabetes. The peer reviewed study, published in Diabetology, a journal dedicated to diabetes research, conducted in collaboration with research groups from the University of Technology Sydney, the University of Wisconsin-Madison, Monash University, the Queensland University of Technology, and the Australian Foundation for Diabetes Research (AFDR), examined the use of engineered scaffolds incorporating extracellular matrix (ECM) derived from a decellularized human pancreas. The work evaluated whether ECM integration could support the function of encapsulated pluripotent stem cell-derived islets within a removable delivery system. The study results demonstrated that when ECM was incorporated into the scaffold, implanted islets exhibited functional performance comparable to encapsulated islets delivered without a scaffold. These findings suggest that biomaterial design and tissue microenvironment play a critical role in supporting islet function and may enable safer, retrievable delivery configurations for future therapeutic development. The research was supported through a Type 1 Diabetes research initiative led by the Australian Foundation for Diabetes Research, which had received donor matched funding for the published study from the National Stem Cell Foundation of Australia. Moreover, it has received dedicated funding from Breakthrough T1D (formerly JDRF), the leading global type 1 diabetes research and advocacy organization, to further develop the underlying model based on the study results. The program integrates proprietary cell differentiation protocols with immune-protective and delivery-oriented design features, with the goal of achieving functional insulin secretion without the need for systemic immunosuppression.お知らせ • Jan 05NewcelX Ltd. Announces Appointment Of Dr. Julien Boisdron To Scientific Advisory BoardNewcelX Ltd. announced the appointment of Dr. Julien Boisdron, MD, a seasoned diabetes expert with extensive experience in Swiss big pharma leadership, to its Scientific Advisory Board. Dr. Boisdron brings more than two decades of global leadership in diabetes care. He currently serves as Chief Medical Officer for a major Swiss-based multinational large cap pharma company, where he oversees the strategic development of next-generation diabetes technologies, clinical programs, and real-world evidence initiatives. His background includes connected-care innovation, advanced insulin-management systems, and the integration of therapeutic and digital solutions to enhance patient outcomes. In joining the NewcelX Scientific Advisory Board, Dr. Boisdron will provide high-level strategic guidance supporting the development of IsletRx, NewcelX's lead therapeutic program, a stem-cell-derived islet cell therapy for insulin-dependent Type 1 Diabetes. Dr. Boisdron will advise on translational strategy as NewcelX advances the program toward clinical trials, including patient-adoption considerations, health-system integration, and future global commercialization frameworks.New Risk • Dec 30New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.75m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪2.2m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Negative equity (-₪51m). Earnings have declined by 6.8% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$9.75m market cap).お知らせ • Nov 18NewcelX Ltd. Announces Appointment of Prof. Jeremy Shefner to the Scientific Advisory BoardNewcelX Ltd. announced the appointment of Prof. Jeremy Shefner, MD, PhD, to the Company's Scientific Advisory Board. Prof. Shefner is a highly respected neurologist specializing in amyotrophic lateral sclerosis (ALS) and neuromuscular disorders. He serves as Professor of Neurology and Chief Medical Officer for Clinical Research at Barrow Neurological Institute in Phoenix, Arizona — an internationally recognized leader in the treatment and research of neurological diseases that is home to one of the largest multidisciplinary brain and spine programs in the United States and the world's largest Phase 0 clinical trials program advancing innovative neurotherapeutics Link. He co-founded the Northeast ALS Clinical Trials Consortium (NEALS) and has published more than 200 peer-reviewed papers on ALS biomarkers, clinical trial design and outcome measures Link. In his role on the SAB of NewcelX, Prof. Shefner will provide strategic guidance on the Company's programs in ALS, including the clinical development of AstroRx, and will support the integration of neuromuscular and neurodegenerative disease expertise into the Company's broader platform of cell therapy and neuroscience innovation.お知らせ • Nov 07NewcelX Ltd. Appoints Tamir Ben-Hur as Scientific Advisory BoardNewcelX Ltd. announced that Professor Tamir Ben-Hur, MD, PhD, a renowned neurologist and long-time scientific advisor of Kadimastem Ltd., will join the Company's Scientific Advisory Board. Prof. Ben-Hur, a Professor of Neurology at Hadassah University Medical Center and the Hebrew University of Jerusalem, is widely recognized as a global expert in neuroimmunology and stem-cell-based regenerative medicine. The commitment of Prof. Ben-Hur to join the NewcelX Scientific Advisory Board represents a strong endorsement of the Merger and the scientific foundation on which NewcelX is being built — uniting Kadimastem Ltd.'s advanced stem-cell platforms and clinical programs with NLS Pharmaceutic Ltd.'s expertise in central nervous system therapeutics.Board Change • Nov 03Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 1 highly experienced director. 2 independent directors (4 non-independent directors). Independent External Director Liora Oren was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.収支内訳NewcelX の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NasdaqCM:NCEL 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Dec 250-81130 Sep 250-131130 Jun 250-181131 Mar 250-121131 Dec 240-71130 Sep 240-51130 Jun 240-31131 Mar 240-31131 Dec 230-31230 Sep 230-41230 Jun 230-52331 Mar 230-62431 Dec 220-62430 Sep 220-72430 Jun 220-72531 Mar 220-82531 Dec 210-82630 Sep 210-82530 Jun 210-72431 Mar 210-72431 Dec 200-72430 Sep 200-72430 Jun 200-72531 Mar 200-72531 Dec 190-72530 Sep 190-72530 Jun 190-72531 Mar 190-72531 Dec 180-62430 Sep 180-62430 Jun 180-62431 Mar 180-62431 Dec 170-62430 Sep 170-62530 Jun 170-72531 Mar 170-62431 Dec 160-52330 Sep 160-52330 Jun 160-52331 Mar 160-42231 Dec 150-42230 Sep 150-412質の高い収益: NCELは現在利益が出ていません。利益率の向上: NCELは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: NCELは利益が出ておらず、過去 5 年間で損失は年間9.7%の割合で増加しています。成長の加速: NCELの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: NCELは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 54.5% ) と比較することは困難です。株主資本利益率高いROE: NCELは現在利益が出ていないため、自己資本利益率 ( -114.48% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/05 22:24終値2026/07/02 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋NewcelX Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jul 02NewcelX Ltd. Announces Successful FDA Pre-IND Meeting With Clear Path Forward For NCEL-101 Toward Starting Clinical Trials For Type 1 DiabetesNewcelX Ltd. announced the successful completion of its Type B Pre-IND meeting with the U.S. Food and Drug Administration. The agency provided constructive feedback and alignment on the Company's proposed development strategy, providing clarity regarding the regulatory pathway toward launching a clinical trial of NCEL-101 for type 1 diabetes in combination with Eledon Pharmaceuticals' anti-CD40L antibody, tegoprubart, an investigational immunomodulatory agent. The meeting results represent a significant milestone toward the clinical development of an innovative treatment paradigm targeting a potential functional cure for type 1 diabetes. The FDA provided favorable feedback on NewcelX's Chemistry, Manufacturing, and Controls processes and preclinical program allowing the Company to proceed toward its Investigational New Drug enabling activities. Combining NCEL-101, an enriched stem cell-derived islet product candidate, with Eledon's anti-CD40L monoclonal antibody, tegoprubart, serving as the cornerstone of a calcineurin inhibitor-free immunosuppressive regimen is designed to enable durable graft survival and function, with the goals of achieving outcomes comparable to donor human islet transplantation. This approach is supported by recently reported results from a 12-patient investigator-initiated study at University of Chicago Medicine in patients with type 1 diabetes, where tegoprubart-based immunosuppression preserved transplanted islet function and maintained durable immune protection. Tegoprubart has been used as an investigational immunosuppressive agent in more than 100 transplant recipients across studies conducted under multiple FDA-cleared IND applications. This body of clinical transplant experience provides important safety, dosing, and immunologic insights that are directly relevant to islet cell replacement therapies and support the planned advancement of NCEL-101. NCEL-101, leveraging a differentiated enrichment process, has demonstrated favorable results in preclinical studies and a supportive safety profile with the following qualities: ~60% Beta cells co express insulin and NKX6.1; MAFA expression, a transcription factor critical for Beta cells maturation and glucose dependent insulin secretion; 99.98% endocrine lineage, implying minimal, if any, off target non-endocrine population; More than 96% of cells are non-proliferative, as donor human islets.
ライブニュース • Jul 01NewcelX Advances NCEL-101 After Positive FDA Pre-IND Meeting for Type 1 DiabetesNewcelX reported a successful FDA Pre-IND meeting for its lead cell therapy candidate NCEL-101, developed in combination with Eledon Pharmaceuticals’ tegoprubart for type 1 diabetes, with the agency providing constructive feedback and outlining a clear path toward IND-enabling activities. The FDA’s favorable view of NewcelX’s manufacturing and preclinical plans allows the company to progress toward formal IND submission, which is a key step before human clinical trials can begin and directly affects the potential timing of its type 1 diabetes program. NewcelX shares trade at US$3.66, with the stock up 75.1% year to date, indicating that the market has already reacted to recent developments around the company’s pipeline. This update moves NCEL-101 from concept toward a more defined regulatory track, while also concentrating risk around execution on IND-enabling work, manufacturing readiness, and future trial design.
お知らせ • Jun 15NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential Of Its Stem Cell Technology PlatformNewcelX announced the publication of a peer-reviewed study in Stem Cell Reports, investigating the potential of AstroRx, a clinical-grade human embryonic stem cells (hESC)-derived astrocyte therapy, which recently completed a successful Phase 1/2a clinical trial in amyotrophic lateral sclerosis (ALS), as a novel and translationally relevant cell therapy for multiple sclerosis (MS), and other chronic demyelinating diseases. The publication further validates NewcelX’s ability to develop novel cell therapies through its stem cell technology platform, designed to generate scalable therapeutic assets across multiple applications. The study, titled “Pro-repair properties of a human embryonic stem cell–derived astrocyte cell therapy in experimental multiple sclerosis,” was developed in collaboration with researchers at several highly regarded institutions, including the Hebrew University of Jerusalem Hadassah Medical School. Data demonstrated that AstroRx addresses key barriers to remyelination by enhancing myelin debris clearance, sustaining a pro-repair inflammatory environment, and promoting the differentiation of oligodendrocyte progenitor cells (OPCs) into mature oligodendrocytes. These effects were observed both in-vitro and in an in-vivo lysolecithin-induced demyelination model. Key findings from the study include the potential for AstroRx® to: enhance myelin debris clearance by microglia, support lymphocyte-mediated immune regulation, and accelerate oligodendrocyte progenitor cell (OPC) differentiation into oligodendrocytes.
お知らせ • Jun 09NewcelX Ltd., Annual General Meeting, Jun 30, 2026NewcelX Ltd., Annual General Meeting, Jun 30, 2026, at 14:00 W. Europe Standard Time. Location: baker mckenzie switzerland ag, holbeinstrasse 30, 8034 switzerland, zurich Switzerland
お知らせ • May 01NewcelX Ltd. announced that it has received $1.349994 million in fundingOn April 30, 2026, NewcelX Ltd. closed the transaction.
お知らせ • Apr 02NewcelX Ltd. announced that it expects to receive $1.349994 million in fundingNewcelX Ltd. announced that it has entered into a securities purchase agreement to issue 490,907 common shares or pre-funded warrants at an issue price of $2.75 per share for gross proceeds of $1,349,994.25 and one series of warrants to purchase 687,270 common shares at an exercise price of $3.025 per share for aggregate proceeds of $1,349,994.25 on April 1, 2026. The offering includes participation from existing shareholders and is expected to close on or about April 15, 2026, subject to the satisfaction of customary closing conditions. The securities are being issued in a private placement under section 4(a)(2) of the securities act of 1933, as amended), and Regulation D promulgated thereunder and have not been registered under the securities act, or applicable state securities laws.
New Risk • Mar 31New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$8.57m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-₪51m). Earnings have declined by 6.8% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$8.57m market cap). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (11% average weekly change).
New Risk • Mar 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪2.2m free cash flow). Negative equity (-₪51m). Earnings have declined by 6.8% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (US$11.9m market cap).
お知らせ • Jan 13Newcelx Ltd. Announces Positive Results from International Collaborative StudyNewcelX Ltd. reported the results of an international collaborative research study investigating advanced biomaterial strategies to support the delivery and function of stem cell-derived islets for the treatment of Type 1 Diabetes. The peer reviewed study, published in Diabetology, a journal dedicated to diabetes research, conducted in collaboration with research groups from the University of Technology Sydney, the University of Wisconsin-Madison, Monash University, the Queensland University of Technology, and the Australian Foundation for Diabetes Research (AFDR), examined the use of engineered scaffolds incorporating extracellular matrix (ECM) derived from a decellularized human pancreas. The work evaluated whether ECM integration could support the function of encapsulated pluripotent stem cell-derived islets within a removable delivery system. The study results demonstrated that when ECM was incorporated into the scaffold, implanted islets exhibited functional performance comparable to encapsulated islets delivered without a scaffold. These findings suggest that biomaterial design and tissue microenvironment play a critical role in supporting islet function and may enable safer, retrievable delivery configurations for future therapeutic development. The research was supported through a Type 1 Diabetes research initiative led by the Australian Foundation for Diabetes Research, which had received donor matched funding for the published study from the National Stem Cell Foundation of Australia. Moreover, it has received dedicated funding from Breakthrough T1D (formerly JDRF), the leading global type 1 diabetes research and advocacy organization, to further develop the underlying model based on the study results. The program integrates proprietary cell differentiation protocols with immune-protective and delivery-oriented design features, with the goal of achieving functional insulin secretion without the need for systemic immunosuppression.
お知らせ • Jan 05NewcelX Ltd. Announces Appointment Of Dr. Julien Boisdron To Scientific Advisory BoardNewcelX Ltd. announced the appointment of Dr. Julien Boisdron, MD, a seasoned diabetes expert with extensive experience in Swiss big pharma leadership, to its Scientific Advisory Board. Dr. Boisdron brings more than two decades of global leadership in diabetes care. He currently serves as Chief Medical Officer for a major Swiss-based multinational large cap pharma company, where he oversees the strategic development of next-generation diabetes technologies, clinical programs, and real-world evidence initiatives. His background includes connected-care innovation, advanced insulin-management systems, and the integration of therapeutic and digital solutions to enhance patient outcomes. In joining the NewcelX Scientific Advisory Board, Dr. Boisdron will provide high-level strategic guidance supporting the development of IsletRx, NewcelX's lead therapeutic program, a stem-cell-derived islet cell therapy for insulin-dependent Type 1 Diabetes. Dr. Boisdron will advise on translational strategy as NewcelX advances the program toward clinical trials, including patient-adoption considerations, health-system integration, and future global commercialization frameworks.
New Risk • Dec 30New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.75m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪2.2m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Negative equity (-₪51m). Earnings have declined by 6.8% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$9.75m market cap).
お知らせ • Nov 18NewcelX Ltd. Announces Appointment of Prof. Jeremy Shefner to the Scientific Advisory BoardNewcelX Ltd. announced the appointment of Prof. Jeremy Shefner, MD, PhD, to the Company's Scientific Advisory Board. Prof. Shefner is a highly respected neurologist specializing in amyotrophic lateral sclerosis (ALS) and neuromuscular disorders. He serves as Professor of Neurology and Chief Medical Officer for Clinical Research at Barrow Neurological Institute in Phoenix, Arizona — an internationally recognized leader in the treatment and research of neurological diseases that is home to one of the largest multidisciplinary brain and spine programs in the United States and the world's largest Phase 0 clinical trials program advancing innovative neurotherapeutics Link. He co-founded the Northeast ALS Clinical Trials Consortium (NEALS) and has published more than 200 peer-reviewed papers on ALS biomarkers, clinical trial design and outcome measures Link. In his role on the SAB of NewcelX, Prof. Shefner will provide strategic guidance on the Company's programs in ALS, including the clinical development of AstroRx, and will support the integration of neuromuscular and neurodegenerative disease expertise into the Company's broader platform of cell therapy and neuroscience innovation.
お知らせ • Nov 07NewcelX Ltd. Appoints Tamir Ben-Hur as Scientific Advisory BoardNewcelX Ltd. announced that Professor Tamir Ben-Hur, MD, PhD, a renowned neurologist and long-time scientific advisor of Kadimastem Ltd., will join the Company's Scientific Advisory Board. Prof. Ben-Hur, a Professor of Neurology at Hadassah University Medical Center and the Hebrew University of Jerusalem, is widely recognized as a global expert in neuroimmunology and stem-cell-based regenerative medicine. The commitment of Prof. Ben-Hur to join the NewcelX Scientific Advisory Board represents a strong endorsement of the Merger and the scientific foundation on which NewcelX is being built — uniting Kadimastem Ltd.'s advanced stem-cell platforms and clinical programs with NLS Pharmaceutic Ltd.'s expertise in central nervous system therapeutics.
Board Change • Nov 03Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 1 highly experienced director. 2 independent directors (4 non-independent directors). Independent External Director Liora Oren was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.